FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars

MoonLake Immunotherapeutics (NASDAQ:MLTX) shares are up during Monday's trading session, trading higher as the company is reporting positive outcomes from its final pre-BLA meeting with the FDA regarding its sonelokimab (SLK) program for hidradenitis suppurativa (HS).